Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats



Status:Recruiting
Conditions:Atrial Fibrillation, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 80
Updated:5/3/2014
Start Date:September 2012
End Date:November 2016

Use our guide to learn which trials are right for you!

Ablation for the Treatment of Concomitant Atrial Fibrillation in Non-Paroxysmal Patients (ATTAC-AF)

The purpose of this study is to demonstrate that the Estech COBRA Surgical System is an
effective treatment for patients with irregular heart beats who are undergoing heart
surgery.

The objective of the trial is to demonstrate that the creation of epicardial and endocardial
lesions with temperature-controlled radiofrequency (TCRF) ablation applied using the Estech
COBRA® Surgical System during concomitant heart surgery is a safe and effective treatment
for non-paroxysmal atrial fibrillation (AF).

Inclusion Criteria:

All subjects are required to meet the following inclusion criteria in order to be
considered eligible for participation in this trial:

1. Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) for
one or more of the following:

1. Mitral valve repair or replacement,

2. Aortic valve repair or replacement,

3. Tricuspid valve repair or replacement, or

4. Coronary Artery Bypass procedures;

2. Subject has history of a non-paroxysmal form of AF for greater than 3 months and has
failed at least one attempt at electrical cardioversion or had a successful attempt
at electrical cardioversion but had a recurrence of AF within 30 days of the
cardioversion;

3. Age 18 to 80 years old;

4. Left ventricular ejection fraction (LVEF) ≥ 30%;

5. Subject has no contraindications to intraoperative transesophageal echocardiography;

6. Subject has a life expectancy greater than 12 months; and

7. Willing and capable of providing Informed Consent to undergo surgery and participate
in all examinations and follow-ups associated with this clinical trial.

A subject is considered to have failed electrical cardioversion if they did not achieve
sinus rhythm for at least 30 seconds following the attempted cardioversion.

Exclusion Criteria:

Subjects will be excluded from participating in this trial if they meet any of the
following exclusion criteria:

1. History of non-paroxysmal AF less than 3 months or for more than 5 years;

2. History of prior cardiac ablative surgical or catheter-based therapy;

3. Previous cardiac surgery (redo) or other intrapericardial procedures;

4. Class IV NYHA heart failure;

5. Known carotid artery stenosis greater than 80% or previous carotid endarterectomy;

6. Wolff-Parkinson-White syndrome;

7. Need for emergent cardiac surgery (e.g., cardiogenic shock);

8. Untreated hyperthyroidism;

9. Untreated hypothyroidism;

10. Acute pulmonary disease;

11. Electrolyte imbalance;

12. History of myocarditis;

13. Presence of a previously implanted device in or adjacent to the treatment target area
that may alter the delivery of therapy (e.g., valvular prosthesis or ring, pacemaker
with leads in coronary sinus or internal defibrillator leads);

14. History of pericarditis;

15. Previous left phrenic nerve paralysis;

16. Bullous lung disease;

17. Presence of active endocarditis, or local or systemic infection;

18. Recent myocardial infarction (< 3 months);

19. Renal failure requiring dialysis or hepatic failure or creatinine of >2 mg/dL
preoperatively;

20. Antiarrhythmic drug therapy required for the treatment of a ventricular arrhythmia;

21. Preoperative need for an intra-aortic balloon pump or intravenous inotropes;

22. Severe peripheral arterial occlusive disease defined as claudication with minimal
exertion;

23. Therapy resulting in compromised tissue integrity including: thoracic radiation,
chemotherapy, long term treatment with oral or injected steroids, or known connective
tissue disorders;

24. Documented left atrial size of 6 cm or more;

25. History of cerebrovascular disease or accident, including stroke or transient
ischemic attack (TIA) within 6 months prior to enrollment;

26. Known contraindication to anticoagulant therapy or inability to comply with
anticoagulant therapy;

27. Pregnancy, planned pregnancy (females of childbearing potential must have a negative
pregnancy test prior to enrollment and agree not to become pregnant during the trial)
or breastfeeding;

28. Forced expiratory volume in 1 second less than 30% of predicted value or need for
home oxygen therapy; or

29. Surgical management of hypertrophic obstructive cardiomyopathy.
We found this trial at
13
sites
2900 W Oklahoma Ave
Milwaukee, Wisconsin 53215
414-649-6000
Aurora St. Luke's Medical Center At Aurora St. Luke's Medical Center, you'll find remarkable treatment...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Columbia, South Carolina 29204
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Evanston, Illinois 60201
?
mi
from
Evanston, IL
Click here to add this to my saved trials
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
80 Seymour St
Hartford, Connecticut 6102
(860) 545-5000
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
Kansas City, Kansas 66160
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
4440 West 95th Street
Oak Lawn, Illinois 60453
708.684.8000
Advocate Christ Medical Center Advocate Health Care, named among the nation
?
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Rochester, Minnesota 55902
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Utica, NY
Click here to add this to my saved trials